Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
Status:
Withdrawn
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This study evaluates nivolumab in combination drug treatments involving 1) nivolumab and
dabrafenib 2) nivolumab and trametinib and 3) nivolumab, dabrafenib and trametinib in
patients with BRAF or NRAS-mutated metastatic melanoma.